Ga68 PET SCAN

NETSPOT®

Health Canada has approved NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection) for the evaluation of neuroendocrine tumours (“NETs”). NETSPOT® is the first and only kit for the preparation of gallium (68Ga) oxodotreotide injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours (GEPNET) for localizing primary tumours and their metastases.

Gallium (68Ga) oxodotreotide injection

NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection)
PRODUCT MONOGRAPH (ENG)
PRODUCT MONOGRAPH (FRE)
Brand Name NETSPOT®
Generic Name kit for the preparation of gallium (68Ga) oxodotreotide injection
Dosage In adult patients – The recommended amount of radioactivity to be administered for PET imaging is up to  2 MBq/kg of body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi).
Indication NETSPOT® [kit for the preparation of gallium (68Ga) oxodotreotide injection], after radiolabeling with gallium (68Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs).
Tumour Type NETs
Contraindications None

Access to NETSPOT®

Health Canada Approval of NETSPOT – PRESS RELEASE

NETSPOT® – Health Canada Approved and Now Available.  Kit for the preparation of gallium (68Ga) oxodotreotide injection

Advanced Accelerator Applications S.A. (AAA), a Novartis company is pleased to announce that Health Canada has approved NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection).

INDICATION

NETSPOT® [kit for the preparation of gallium (68Ga) oxodotreotide injection], after radiolabeling with gallium (68Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs).

FOR MORE INFORMATION:

Please consult the Product Monograph at https://www.adacap.com/our-products/ for important product information relating to dosing information, drug interactions and adverse reactions. The Product Monograph is also available by calling AAA Customer Service at Tel: 1-844-367-3222.

Access to NETSPOT® in Canada

NETSPOT is available at the following clinic in BC.   Patients will require a physician referral (referral form is available on their website at initiomedical.ca). Cost is $5,200.

Initio Medical Group Inc.
#300-3185 Willingdon Green, Burnaby, BC, V5G 4P3
Phone: 604-678-9274
Fax: 604-678-9274

Sunnybrook Health Sciences Centre
3075 Bayview Avenue, Toronto, ON

KMH Labs
2075 Hadwen Road, Mississauga, ON

CISSS de Laval
1755, boul. René-Laennec, Laval, QC

CIUSSS MCQ – Trois-Rivieres
1991, Boulevard du Carmel, Trois-Rivieres, QC

CHU – Sainte Justine
3175 chemin de la Cote-Sainte-Catherine, Montreal, QC

CISSS CA – Secteur Alphonse- Desjardins (Lévis)
100 Rue Monseigneur-Bourget, Lewis, QC

CIUSSS Saguenay Lac-St-Jean
305 Rue St-Vallier, Chicoutimi, QC